2023 Corporate Governance Statement and Appendix 4G
Released
Released
Announcement PDF
25 October 2023
Manager, Company Announcements
ASX Limited
Level 4
20 Bridge Street
SYDNEY NSW 2000
Via E-Lodgement
2023 Corporate Governance Statement
In accordance with the Listing Rules, attached for release to the market is the Mayne Pharma 2023
Corporate Governance Statement and accompanying Appendix 4G.
The Corporate Governance Statement has been approved by the Board and this announcement is
authorised for release by the Chair.
Yours faithfully
Laura Loftus
Company Secretary
For further information contact:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
2023 CORPORATE GOVERNANCE STATEMENT
The Board of Directors of Mayne Pharma Group Limited (ASX:MYX) (“Company” or “Mayne Pharma”) is responsible for the corporate
governance of the Group and is committed to applying the ASX Corporate Governance Council Corporate Governance Principles and
Recommendations (“ASX Principles”). The Board guides and monitors the business and affairs of the Company on behalf of its shareholders.
The Board requires the Company to maintain high standards of ethics and integrity at all times.
The ASX Principles are an important regulatory guide for listed companies reporting on their corporate governance practices. Under ASX
Listing Rule 4.10.3, listed companies must disclose the extent to which they have followed the ASX Principles, and if any of the
recommendations have not been followed, explain why. The Board believes that the Company’s policies and practices comply in all
substantial respects with the 4th Edition of the ASX Principles.
Important information relating to the Company’s corporate governance policies and practices are set out on the Company’s website at
maynepharma.com. The following documents are available on the corporate governance section of the website:
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
Corporate Governance Statement;
Anti-Bribery and Anti-Corruption Policy;
Audit and Risk Committee Charter;
Board Charter;
Business Code of Conduct;
Diversity Policy;
Market Disclosure Policy;
Misconduct and Whistleblowing Policy;
Modern Slavery Report;
Nomination Committee Charter;
Remuneration and People Committee Charter;
Science, Technology and Medical Committee Charter;
Securities Trading Policy;
Supplier Code of Conduct; and
Equal Opportunity Report.
The Company will continue to update its policies and practices to reflect developing corporate governance requirements and practices.
1.
The Board of Directors
1.1
The Board’s duties
The role of the Board is to oversee and guide the management of the Company with the aim of protecting and enhancing
the interests of its shareholders and taking into account the interests of other stakeholders including employees and the
wider community. In addition, the Board is responsible for identifying areas of significant business risk and ensuring
arrangements are in place to adequately manage those risks.
The Board is responsible for setting the strategic direction and objectives of the Company, establishing goals for management
and monitoring the achievement of those goals. The Chief Executive Officer (CEO) is responsible to the Board for the day-today management of the Group. The Board ensures that the CEO is appropriately qualified and experienced to discharge their
responsibilities and has procedures in place to assess the performance of the CEO.
The Board has adopted a formal charter (“Board Charter”) that clearly establishes the relationship between the Board and
management and describes their functions and responsibilities. The Board Charter was last reviewed in October 2023. The
Board Charter is posted on the corporate governance section of the Company’s website.
The Board also appoints the Company Secretary. The Company Secretary is responsible for coordination of all Board business
including agendas, Board papers and minutes, advising the Board and committees on governance matters and helping to
facilitate and organise the induction and professional development of Directors.
1.2
Code of Conduct
Directors of the Company and Company employees are subject to the Company’s Business Code of Conduct (see further
discussion below in the Conduct and Ethics section). The Business Code of Conduct is considered by the Board to be an
effective way to guide the behaviour of all Directors and employees and demonstrates the Company’s commitment to ethical
and compliant practices.
Mayne Pharma Corporate Governance Statement 2023
1
1.3
Board Composition
The composition of the Board is determined in accordance with the following principles and guidelines:
▪
▪
▪
▪
▪
the Board should comprise at least three Directors;
the Board should comprise a majority of independent Non-Executive Directors;
the Board should comprise Directors with an appropriate range of skills, experience and expertise;
the Chair should be an independent Non-Executive director; and
the Board shall meet regularly and follow meeting guidelines set down to ensure all Directors are made aware of and
have available all necessary information, to participate in an informed discussion of all agenda items.
The Board currently comprises seven Directors. There are six Non-Executive Directors and one Executive Director. Details of
the Directors are included on the ‘About’ section of the Company’s website.
Non-Executive Director
Period in office as at 1 October 2023
Mr Condella
5 years and 4 months
Professor Robinson
9 years and 1 months
Mr Blake
5 years and 4 months
Dr MacFarlane
1 year and 8 months
Ms Custin
1 year and 6 months
Mr Petrie
1 year and 1 month
Average NED tenure
4 years
The Board seeks to maintain an appropriate mix of skills and diversity in the membership of the Board. This includes diversity
of skills, experience, location and gender, as well as background in the pharmaceutical industry, international business,
finance, accounting and management.
The following Board skills matrix describes the combined skills of the Board across a range of general and specialist areas.
The Board considers that collectively the Directors have the appropriate range of skills and experience necessary to direct
the Company’s businesses and achieve the Company’s strategic objectives.
BOARD SKILLS MATRIX
Director, senior executive, or equivalent experience in developing and
implementing successful strategies and plans to drive both organic growth and
inorganic growth through business development activities.
Senior executive or equivalent experience in pharmaceutical product
Commercial
commercialisation including product development; regulatory requirements;
marketing, sales, and reimbursement; application of new technologies such as
digital services; and the effective use of legal services to support enterprise success.
Senior executive or equivalent exposure to a range of political, cultural, regulatory,
Worldview
and business environments. Ability to manage and oversee an organisation's
business and strategic objectives from an international perspective.
Senior executive or equivalent experience in a pharmaceutical, pharma services,
Industry
biotech, or healthcare delivery organisation with detailed understanding of
knowledge
healthcare industry dynamics in the Company's target markets.
Director, senior executive or equivalent experience in financial accounting and
Finance
reporting, corporate finance, internal controls, risk management, and corporate
governance including compliance with applicable financial market regulations.
Senior executive or equivalent experience with large capital projects,
Operations
manufacturing, quality operations, and global supply chains within a healthcare,
biopharmaceutical, or pharmaceutical organisation.
Human Resources Experience in succession planning, developing remuneration and incentive
programs, recruitment and retention of key talent, and environmental, health and
safety risks in the workplace.
Strategy
Mayne Pharma Corporate Governance Statement 2023
BOARD
REPRESENTATION
7
6
7
6
7
6
7
2
Directors are expected to maintain the skills and knowledge required to discharge their duties and obligations. The Board is
provided with Board papers, presentations, briefings, and information related to material developments in laws, regulations
and industry frameworks that may affect the Mayne Pharma business. Directors are expected to undertake any necessary
continuing professional education and training.
1.4
Independence of Directors
The Board recognises the important contribution that independent Directors make to good corporate governance. Each
Director is required to bring unfettered and independent judgement.
The Board has reviewed the position and associations of each of the seven Directors in office at the date of this statement
and considers that six of the Directors are independent. In considering whether a Director is independent, the Board has
regard to the independence criteria in ASX Principle 2 and other facts, information and circumstances that the Board
considers relevant. The Board assesses the independence of new Directors upon appointment and reviews their
independence, and the independence of other Directors, at least annually.
The Board considers that Mr Condella, Mr Blake, Ms Custin, Dr MacFarlane, Mr Petrie and Professor Robinson meet the
independence criteria in ASX Principle 2 and have no material business or contractual relationship with the Company, other
than as a Director. In considering the independence of the Directors, the Board considered each Director’s tenure and
concluded that no Director has held office for such a period as to interfere with the exercise of independent judgement. Mr
O’Brien is employed in an executive capacity therefore he is not considered to be independent.
The Directors will continue to monitor the composition of the Board to ensure its structure remains appropriate and
consistent with effective management and good governance.
1.5
Retirement and Re-Election of Existing Directors
The Constitution of the Company requires one third of the Directors, other than Executive Directors, to retire from office at
each Annual General Meeting. Directors who have been appointed by the Board during the year are required to retire from
office at the next Annual General Meeting and are not taken into account in determining the number of Directors to retire
at that Annual General Meeting. Directors cannot hold office for a period in excess of three years, or later than the third
Annual General Meeting following their appointment, without submitting themselves for re-election. Retiring Directors are
eligible for re-election by shareholders.
1.6
Nomination and Appointment of New Directors
Recommendations of candidates for new Directors are made by the Nomination Committee for consideration by the Board
as a whole. If it is necessary to appoint a new Director to fill a vacancy on the Board or to complement the existing Board, a
wide potential base of possible candidates is considered.
In making recommendations to the Board regarding the appointment of Directors, the Nomination Committee periodically
assesses the appropriate mix of skills, experience and expertise required by the Board and the extent to which the required
skills and experience are represented on the Board. The committee also takes account of other factors such as diversity and
cultural fit. The identification of a potential Director may be assisted by the use of external search organisations and detailed
background information, including appropriate checks in relation to the potential candidate, is provided to all Directors prior
to any decisions being made. Nominations for appointment are then approved by the Board as a whole.
If a candidate is recommended by the Nomination Committee, the Board assesses that proposed new Director against a
range of criteria including background, experience, professional skills, personal qualities, the potential for the candidate’s
skills to augment the existing Board and the candidate’s availability to commit to the Board’s activities. If these criteria are
met and the Board appoints the candidate as a Director, that Director must retire at the next Annual General Meeting of
shareholders and will be eligible for election by shareholders at that Annual General Meeting.
New Directors are provided with a letter of appointment, setting out the terms of their appointment, including their powers,
rights and obligations. An induction program is provided for new Directors to familiarise them with the business, history,
culture, key risks, Board practices and procedures. This includes meetings with senior executives, site visits, provision of
relevant corporate governance materials and policies and discussions with the Chair and other Directors.
1.7
Board Meetings
The Board meets formally at least nine times each year, and from time to time meetings are convened outside the scheduled
dates to consider matters of importance. The Board met 20 times between 1 July 2022 and 30 June 2023.
The Directors’ attendance at Board meetings is detailed in the Annual Report.
The agenda for meetings is prepared by the Company Secretary, in conjunction with the Chair, CEO, and periodic input from
the Board. Comprehensive Board papers are distributed to Directors in advance of scheduled meetings. Board meetings are
held virtually by videoconference, or in person at the Company’s registered head office and manufacturing facility based in
Salisbury, South Australia or at the Company’s commercial offices in Melbourne, Victoria and Raleigh, North Carolina, USA.
The Non-Executive Directors also meet regularly without management present.
Mayne Pharma Corporate Governance Statement 2023
3
1.8
Performance Review
The Board acknowledges the importance of regularly reviewing its own performance and effectiveness as well as the
performance and effectiveness of its Committees and individual Directors.
The Board conducts an annual assessment of its performance and effectiveness. The performance evaluation involves the
Directors completing an anonymous questionnaire/survey with results collated online. This annual assessment also covers
the performance and effectiveness of the Board Committees. The Board discusses the outcomes of the survey and areas for
improvement. The evaluation may establish goals and objectives for the Board and provide any recommendations for
improvement to Board performance. Each Director’s performance is evaluated annually by the Chair and the Chair invites
Directors to evaluate his performance. The last Board performance evaluation was completed in June 2023.
1.9
Board Members’ Rights to Independent Advice
The Board has procedures to allow Directors, in the furtherance of their duties as Directors or members of a Board
Committee, to seek independent professional advice at the Company’s expense, subject to the prior written approval of the
Chair.
2.
Board Committees
The Board has established the following committees to advise and support the Board in carrying out its duties:
▪
▪
▪
▪
Audit and Risk Committee;
Nomination Committee;
Remuneration and People Committee; and
Science, Technology and Medical Committee.
Directors’ attendance at meetings of these committees is detailed in the Annual Report.
2.1
Audit and Risk Committee
It is the Board’s responsibility to ensure that an effective internal control framework exists within the Company, including
internal controls to deal with both the effectiveness and efficiency of significant business processes. Effective internal
controls include the safeguarding of assets, the maintenance of proper accounting records, managing and mitigating business
risks and the reliability of financial information.
The Board has established an Audit and Risk Committee to assist and advise the Board in fulfilling its responsibilities to
oversee the Company’s internal control framework, financial reporting obligations, risk management and adherence to legal
and regulatory requirements. The Audit and Risk Committee operates under a Charter approved by the Board. The Charter
was last reviewed and approved by the Board in October 2023.
The duties and responsibilities of the Audit and Risk Committee include:
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
ensuring appropriate accounting policies and procedures are defined, adopted and maintained;
ensuring that the operating and management reporting procedures, and the system of internal control, are of a
sufficiently high standard to provide timely, accurate and relevant information as a sound basis for management of
the Company’s business;
reviewing the Financial Statements for accuracy and to ensure they reflect a true and fair view, prior to their
presentation to the Board;
reviewing the scope of work including approval of annual audit plans and effectiveness of the external and internal
audit (if any) functions within the Company;
where an internal audit function exists, appointing, on recommendation by the CEO or CFO, a person(s) responsible
for internal audit functions as specified from time to time and reviewing the scope and adequacy of the internal audit
work plan and the independence, objectivity and performance of the internal audit function;
making recommendations to the Board of Directors on the appointment, reappointment or replacement of the
external auditors (subject, if applicable, to shareholder ratification), and monitoring the effectiveness and
independence of the external auditors;
reviewing and approving the terms of engagement and fees of external auditors;
reviewing and making recommendations to the Board of Directors on the rotation of the audit engagement partner
and the scope and the adequacy of the external audit;
reviewing and assessing non-audit and assurance-related services to be provided by external auditors, and considering
the potential for those services to compromise external auditors’ judgement or the auditor independence
requirements under the Corporations Act 2001 (Cth) (“Corporations Act”); and
obtaining an independence declaration from each external auditor, as required.
As and when required, the Audit and Risk Committee engages external consultants to review various aspects of the Group’s
internal control environment, as the Company does not yet have an internal audit function. The Global Compliance and Risk
function periodically assesses the existence and adherence to established policies and procedures throughout the Company.
The Company through external consultants conducts multiple monitoring programs to test critical areas of the business. The
Compliance and Risk function conducts regular meetings with leaders in key operational functions like Finance, Environment
Health & Safety, Human Resources and Legal, in addition to each of the Business Units and maintains an open line of
communication with the Audit and Risk Committee. Separately, the Compliance and Risk function is responsible for leading
Mayne Pharma Corporate Governance Statement 2023
4
the implementation of the Company’s risk framework. This risk framework requires each business unit and functional leader
to formally consider its risk environment, document identified risks and risk treatment plans, and periodically report on the
progress of ongoing risk mitigation through the implementation of those treatment plans.
The operation and responsibilities of the Audit and Risk Committee are consistent with ASX Principle 4 and ASX Principle 7.
The Committee met 14 times during the financial year ended 30 June 2023.
The members of the Audit and Risk Committee at the date of this statement are:
▪
Ms A Custin – Chair;
▪
Mr P Blake; and
▪
Mr D Petrie.
In addition to the members of the Committee, the CFO attends the Audit and Risk Committee meetings and representatives
of the external auditors and other members of management are invited to attend when appropriate.
2.2
Appointment of external auditors
The Audit and Risk Committee is responsible for making recommendations to the Board of Directors on the appointment,
reappointment or replacement (subject, if applicable, to shareholder ratification) and the remuneration of the external
auditors, and is responsible for monitoring of effectiveness and independence of the external auditors, including resolution
of disagreements between management and the auditor regarding financial reporting.
The appointed external auditor is required to attend the Company’s Annual General Meeting to answer any questions from
shareholders in relation to the audit.
The Committee must approve all audit and non-audit services provided by the external auditors and must not engage the
external auditors to perform any non-audit/assurance services that may impair or appear to impair the external auditor’s
judgement or independence in respect of the Company. The Committee may delegate the approval authority to a member
of the Committee. The decisions of any Audit and Risk Committee member to whom the approval authority is delegated
must be presented to the full Committee at its next scheduled meeting.
When reviewing the auditor’s independence, the Committee will typically require the rotation of the audit partner at least
once every five years, in accordance with the Corporations Act. A new audit partner commenced for the 2019 financial year.
Following completion of a tender process in 2023, and upon the recommendation of Management and the Audit and Risk
Committee, the Board is recommending that shareholders approve the appointment of a new auditor at the Company’s 2023
Annual General Meeting.
2.3
Nomination Committee
The Board has established a Nomination Committee to assist the Board in selecting candidates for the position of Director.
The members of the Nomination Committee at the date of this statement are:
▪
Mr F Condella - Chair
▪
Dr K MacFarlane; and
▪
Prof B Robinson.
The purpose of the Nomination Committee as set out in its Charter is to assist and advise the Board in fulfilling its
responsibilities to shareholders on matters relating to the nomination and succession planning of the Directors of Mayne
Pharma. The Charter was last reviewed and approved by the Board in October 2023.
The duties and responsibilities of the Nomination Committee include:
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
supporting and advising the Board in fulfilling its responsibilities to shareholders in ensuring that the Board is
comprised of individuals who are best able to discharge the responsibilities of Directors having regard to the law and
standards of governance;
developing and reviewing a Board skills matrix setting out the skills, experience and expertise required on the Board,
the extent to which these are represented on the Board and those that the Board is looking to achieve in is membership
including any emerging or governance issues;
making recommendations to the Board on the necessary and desirable competencies of new Directors to the Board;
reviewing and making recommendations to the Board regarding the structure, size and composition of the Board and
the effectiveness of the Board as a whole;
establishing processes for the identification and recruitment of suitable candidates for appointment to the Board and
for the re-election of Directors;
developing Director induction programs that are undertaken by new Directors and assessing if professional
development opportunities are needed to address emerging business and governance issues;
establishing processes for evaluating the performance of individual Directors and the Board as a whole;
reviewing the policies in relation to retention and termination of the CEO and key leadership roles;
overseeing the succession plans and processes for the CEO and other key leadership roles and review the pool of
internal candidates to fill these positions; and
developing succession plans for the Board.
The operation and responsibilities of the Nomination Committee are consistent with ASX Principle 2.
Mayne Pharma Corporate Governance Statement 2023
5
The Committee met once during the financial year ended 30 June 2023.
2.4
Remuneration and People Committee
The Board has established a Remuneration and People Committee to assist the Board in ensuring that appropriate and
effective remuneration and other people-related policies are in place that support the Company’s strategy and objectives
and to review these on behalf of the Board.
The members of the Remuneration and People Committee at the date of this statement are:
▪
Mr F Condella - Chair;
▪
Mr P Blake; and
▪
Mr D Petrie.
The duties and responsibilities of the Remuneration and People Committee are set out in its Charter which was last reviewed
and approved by the Board in October 2023. The key duties and responsibilities of the Committee include:
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
reviewing and overseeing the Company’s key people and organisational culture strategies and their alignment with
the overall strategy and vision;
reviewing and endorsing remuneration strategies and policies, at least every three years or more frequently if
required;
recommending to the Board any changes in remuneration policy including superannuation, other benefits and
remuneration structure for executives and which is likely to have a material impact on the Company;
considering and recommending to the Board on an annual basis the remuneration policies and packages for the CEO,
for direct reports to the CEO and for the business as a whole;
reviewing and recommending to the Board proposals for employee equity plans;
reviewing and recommending to the Board proposals for short- and long-term incentive programs for executives;
reviewing and recommending to the Board any changes to the remuneration framework for Directors, including NonExecutive Directors’ fees;
ensuring there is a proper performance management process in place throughout the organisation and that it is
operating effectively;
being informed of current trends in executive remuneration and associated incentive initiatives and legislative issues
associated with executive remuneration programs;
reviewing talent management processes and strategy, ensuring alignment with overall People & Culture strategy and
monitoring operational effectiveness of talent management processes;
reviewing the Company’s policies in respect of diversity, including strategies or changes to address any gender pay
gap;
reviewing and reporting to the Board on progress against the measurable objectives contained in the Diversity Policy;
reviewing and report to the Board the proportion of women and people of colour employed by the Company overall
and at each level of the Company, making recommendations where appropriate;
reviewing the Remuneration Report contained in the Company’s Annual Report and make recommendations to the
Board for approval; and
ensuring compliance with ASX corporate governance practices and the ASX Listing Rules, and other relevant
regulations.
A brief discussion on the Company’s remuneration policies in respect of Directors and executives is set out in the Annual
Report. Detailed disclosure of the remuneration paid to the Company’s Directors and executives is set out in the
Remuneration Report, which forms part of the Annual Report.
The Committee met ten times during the financial year ended 30 June 2023.
2.5
Science, Technology and Medical Committee
The Board has established a Science, Technology and Medical Committee to assist and advise the Board in overseeing the
strategic direction and investment in research and development and other scientific initiatives of the Company.
The members of the Science, Technology and Medical Committee at the date of this statement are:
▪
Prof B Robinson - Chair; and
▪
Dr K MacFarlane.
In addition to the members of the Committee, other members of management are also invited to attend meetings of the
Committee when appropriate.
The Committee has the following responsibilities to assist the Board in its oversight of the Company’s scientific and
therapeutic strategies:
▪
▪
▪
▪
reviewing any potential or new scientific and therapeutic initiatives by the Company that could have an impact on its
overall growth, performance and/or competitive position;
reviewing the scientific and therapeutic aspects of the Company’s investments in technology through acquisition, inlicensing or other business development activities;
reviewing scientific and therapeutic trends that could have a significant impact on the Company and more generally,
the industry; and
reviewing ongoing development and clinical trial activity of the Group.
Mayne Pharma Corporate Governance Statement 2023
6
The Committee Charter was last reviewed and approved by the Board in October 2023.
The Committee met three times during the financial year ended 30 June 2023.
3.
Risk Management and Financial Reporting
3.1
Risk Identification and Management
The Board accepts that taking and managing risk is central to building shareholder value and the Board is responsible for the
Group’s risk management strategy. Management is responsible for implementing the Board’s strategy and for developing a
control infrastructure designed to identify and mitigate risks across operations.
The Company employs executives with the requisite experience and qualifications to enable the Board to manage the risks
to the Company. The Board has requested the Audit and Risk Committee oversee the Group’s risk management processes
and procedures.
The Company has implemented a Risk Management Policy with a detailed, structured approach to systematically identify,
rank, mitigate, and monitor risks. This effort, led by the Compliance and Risk function, is additive to ongoing risk management
responsibilities that all employees engage in as they accomplish their daily tasks according to Company requirements. The
Company maintains a risk register and material risks are regularly reported on and discussed with management, the Audit &
Risk Committee and the Board.
The Group’s identification and management of business risks
Share your feedback
Discover